Close



Sep 26, 2023 05:05PM
Mar 31, 2023 06:23AM
Mar 29, 2023 04:00PM
Jan 4, 2023 04:01PM
Jan 4, 2023 04:00PM
Dec 12, 2022 02:30AM
Nov 28, 2022 04:00PM Inventiva (IVA) secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US
Nov 28, 2022 04:00PM
Nov 21, 2022 04:01PM
Nov 21, 2022 04:00PM
Nov 10, 2022 04:00PM
Oct 31, 2022 03:00AM
Oct 21, 2022 04:00PM
Sep 22, 2022 02:30AM Inventiva reports its 2022 first-half financial results and provides a corporate update
Sep 21, 2022 04:40PM
Mar 8, 2022 05:51AM
Mar 8, 2022 02:00AM
Mar 7, 2022 04:26PM
Mar 7, 2022 04:00PM
Mar 1, 2022 04:00PM
Feb 28, 2022 04:00PM Inventiva announces the schedule of publication and presentation of its 2021 Full-Year Financial Results
Feb 14, 2022 04:00PM
Jan 31, 2022 04:00PM
Jan 31, 2022 04:00PM
Jan 20, 2022 04:00PM
Dec 16, 2021 04:00PM
Dec 6, 2021 04:00PM
Nov 10, 2021 04:00PM Inventiva reports 2021 Third Quarter Financial Information
Nov 3, 2021 04:00PM
Oct 27, 2021 04:00PM
Oct 20, 2021 05:07PM
Oct 18, 2021 04:00PM
Sep 28, 2021 04:00PM
Sep 23, 2021 02:45AM
Sep 21, 2021 04:01PM Inventiva (IVA) Granted FDA's Fast Track Designation of lanifibranorin NASH Encompasses the Treatment of NASH with Compensated Cirrhosis
Sep 21, 2021 04:00PM
Sep 20, 2021 04:10PM
Sep 16, 2021 04:00PM
Sep 10, 2021 09:00AM
Sep 8, 2021 04:00PM
Aug 30, 2021 04:00PM
Aug 2, 2021 05:01PM Inventiva (IVA) announces implementation of At-The-Market program for Up to $100M
Aug 2, 2021 05:00PM
Jul 28, 2021 04:00PM
Jun 9, 2021 04:00PM
Apr 19, 2021 04:00PM
Mar 4, 2021 04:00PM
Feb 25, 2021 04:00PM
Jan 5, 2021 04:00PM Inventiva announces design of Phase III clinical trial with lanifibranor in NASH
Dec 7, 2020 04:00PM

251,687 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All